Roche eyes quick FDA approval in SMA race with Biogen, Novartis

Roche expects its risdiplam medicine for spinal muscular atrophy (SMA) to get U.S. approval by May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area.

from Reuters: Health News https://ift.tt/2DjVwOF
via IFTTT